Cancer in patients with rheumatic diseases exposed to different biologic and targeted synthetic DMARDs in realworld clinical practice: data from a multicenter register
14/08/2023
I. Castrejón Fernández1 , J. Molina Collada1,2, C. Pérez García3, P. Vela-Casasempere4, C. Díaz Torne5, C. Bohórquez6 , J.M. Blanco Madrigal7 and F. Sánchez-Alonso8
SER 2022
C019
https://static.elsevier.es/reuma/reumacongreso2022.pdf